NLX-101 is under clinical development by Neurolixis and currently in Phase I for Fragile X Syndrome. According to GlobalData, Phase I drugs for Fragile X Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NLX-101 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NLX-101 overview
NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug candidate acts by targeting 5-hydroxytryptamine (5-HT)1A receptor.
Neurolixis overview
Neurolixis is an early-stage biopharmaceutical company that focuses on novel drugs for the treatment of human central nervous system diseases. Its pipeline product portfolio includes NLX-112, a drug candidate intended for the treatment of L-DOPA-induced dyskinesia; and NLX-101 is a drug used for the treatment of breathing difficulties in Rett’s syndrome, a genetically-encoded orphan disorder. The company offers treatment solutions for human central nervous system disorders such as Parkinson’s disease, Rett syndrome, depression and schizophrenia. Neurolixis is headquartered in Dana Point, California, the US.
For a complete picture of NLX-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
